News

PD-1+ NSCLC Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
The leading PD-1+ NSCLC Companies such as Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others. Promising PD-1+ ...
GEN - Genetic Engineering and Biotechnology News2d
Absci Advances Lead AI-Designed Candidate for IBD into the Clinic
Absci has entered the clinic with its AI-designed antibody, dosing first volunteers in a trial targeting TL1A for ...
Applied Clinical Trials Online16d
iTeos and GSK Halt TIGIT Antibody Belrestotug Development After Phase II Trials Miss Efficacy Marks in NSCLC and HNSCC
Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...
Fintel on MSN2d
Wedbush Downgrades iTeos Therapeutics (ITOS)
Fintel reports that on May 28, 2025, Wedbush downgraded their outlook for iTeos Therapeutics (NasdaqGM:ITOS) from Outperform ...
Fintel on MSN2d
Wells Fargo Downgrades iTeos Therapeutics (ITOS)
Fintel reports that on May 28, 2025, Wells Fargo downgraded their outlook for iTeos Therapeutics (NasdaqGM:ITOS) from ...
Compugen Ltd. (NASDAQ:CGEN) Q1 2025 Earnings Call Transcript
Compugen Ltd. (NASDAQ: CGEN) Q1 2025 Earnings Call Transcript May 19, 2025 Compugen Ltd. misses on earnings expectations.
Pharmabiz12d
SEC recommends to upgrade Corbevax from restricted use in emergency situation to new drug
SEC recommends to upgrade Corbevax from restricted use in emergency situation to new drug: Gireesh Babu, New Delhi Monday, ...
TMCnet9d
Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19
Invivyd plans to engage FDA shortly on an expedited pathway to develop high-quality, scalable COVID-19 prevention and treatment options urgently needed by high-risk populations identified by the FDA ...